Ali Behbahani
Sits on 7 boards. Overboarded · 7 public boards Last updated September 27, 2026
Time on boards
- Boards served
- 7
- Current seats
- 7
- Board service
- 20 years
- Director since
- 2023
20 years of board service in total across 7 boards, counting each seat separately. Longest: Black Diamond Therapeutics Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Nkarta Inc. June 10, 202668.9%
-
CRISPR Therapeutics AG June 4, 202672.9%
-
Black Diamond Therapeutics Inc. June 12, 202542.1%
-
CRISPR Therapeutics AG June 5, 202572.5%
-
Monte Rosa Therapeutics Inc. June 12, 202460.2%
-
Korro Bio Inc. June 11, 202471.4%
-
CRISPR Therapeutics AG May 30, 202465.7%
-
Nkarta Inc. June 9, 202368.2%
-
CRISPR Therapeutics AG June 8, 202355.3%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 18, 2026 | Black Diamond Therapeutics Inc. | Grant or award | +7,707 | $1.93 | $14,875 |
| Sep 17, 2026 | CRISPR Therapeutics AG | Option exercise | +30,000 | $14.00 | $420,000 |
| Sep 17, 2026 | CRISPR Therapeutics AG | Open-market sale | −13,679 | $57.09 | $780,935 |
| Jul 1, 2026 | Monte Rosa Therapeutics Inc. | Other | −1,000,000 | — | — |
| Jul 1, 2026 | Monte Rosa Therapeutics Inc. | Other | +15,000 | — | — |
| Jul 1, 2026 | Monte Rosa Therapeutics Inc. | Other | −15,000 | — | — |
| Jun 19, 2026 | Black Diamond Therapeutics Inc. | Grant or award | +8,961 | $1.66 | $14,875 |
| Mar 20, 2026 | Black Diamond Therapeutics Inc. | Grant or award | +6,919 | $2.15 | $14,876 |
| Mar 10, 2026 | Korro Bio Inc. | Grant or award | +207,100 | $11.11 | $2,300,881 |
| Feb 9, 2026 | SpyGlass Pharma Inc. | Derivative conversion | +1,619,240 | — | — |
| Feb 9, 2026 | SpyGlass Pharma Inc. | Derivative conversion | +1,370,168 | — | — |
| Feb 9, 2026 | SpyGlass Pharma Inc. | Derivative conversion | +1,370,168 | — | — |
| Feb 9, 2026 | SpyGlass Pharma Inc. | Derivative conversion | +737,962 | — | — |
| Feb 9, 2026 | SpyGlass Pharma Inc. | Open-market purchase | +937,500 | $16.00 | $15,000,000 |
| Feb 9, 2026 | SpyGlass Pharma Inc. | Derivative conversion | +954,990 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.